NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Over half of new drugs budget already committed

By David Lynch - 06th Jul 2021

Health themes. Background of a large group of assorted capsules, pills and blisters. Drug abuse.

Some €30 million of the €50 million allocated by the HSE for new drugs this year had already been committed by the end of March, this newspaper has been told. The issue was raised at the March meeting of the HSE drugs group, where it was noted that the Executive’s National Service Plan (NSP) 2021 made a provision of €50 million for new drugs in 2021.

“Nineteen applications have now been supported by the HSE executive management team (EMT) from this allocation,” read the minutes from the meeting.

“These applications have an estimated additional cost to the HSE of €30 million in 2021 and an estimated five-year cost amounting to €260 million.”

A HSE spokesperson told the Medical Independent that €30 million of the 2021 new drugs budget had been committed by March, “as was expected when the provision was made.”

The HSE did not provide a figure for new drug applications supported by the EMT since March, noting that “applications are processed each month on an ongoing basis and new medicines tend to be approved and progressed each month”. The HSE considers the five-year costs of new medicines as part of its decision-making processes.

Leave a Reply

Latest Issue
The Medical Independent 26th September 2023

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read